Cite
PCN96 - Cost-Effectiveness Analysis of Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in the United States.
MLA
Tremblay, G., et al. “PCN96 - Cost-Effectiveness Analysis of Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in the United States.” Value in Health, vol. 19, no. 3, May 2016, p. A151. EBSCOhost, https://doi.org/10.1016/j.jval.2016.03.1595.
APA
Tremblay, G., Pelletier, C., Copher, R., Forsythe, A., & Majethia, U. (2016). PCN96 - Cost-Effectiveness Analysis of Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in the United States. Value in Health, 19(3), A151. https://doi.org/10.1016/j.jval.2016.03.1595
Chicago
Tremblay, G, C Pelletier, R Copher, A Forsythe, and U Majethia. 2016. “PCN96 - Cost-Effectiveness Analysis of Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in the United States.” Value in Health 19 (3): A151. doi:10.1016/j.jval.2016.03.1595.